HIV Infections
Conditions
Keywords
Nevirapine, Atazanavir, Pharmacokinetics, Interactions
Brief summary
The purpose of this study is to evaluate the influence of nevirapine in exposure to atazanavir boosted with ritonavir, in steady state equilibrium, in HIV-infected adult patients.
Detailed description
In recent years, new treatment strategies have appeared aimed at reducing the risk of treatment-derived toxicity without compromising efficacy. Of the recent antiretroviral drugs, atazanavir is a protease inhibitor (PI) whose pharmacokinetic profile allows it to be given in a single daily take with a scant impact on lipid metabolism. This second characteristic makes atazanavir a good alternative for patients with a high vascular risk. However, one of its drawbacks is that it may present clinically relevant interactions with other drugs. Another antiretroviral agent with a scant impact on lipid metabolism is nevirapine. Different studies have described an improvement in lipid profile, as well as a less atherogenic tendency in patients treated with nevirapine. Moreover, the combination of nevirapine with PI drugs in the context of nucleoside-sparing strategies may permit a suitable control of viral replication, and an improvement in the mitochondrial toxicity derived from treatment with NTRI, which may possibly result in a minor incidence or in a clinical improvement of lipodystrophy. The combination of atazanavir with nevirapine may be of major interest in HIV-infected patients that have had a cardiovascular event (secondary prevention) or are at a high risk of having one (primary prevention). Similarly, this combination of drugs may be promising as a nucleoside-sparing strategy. However, according to preliminary data, the joint administration of nevirapine with atazanavir may lead to a reduction in the atazanavir plasma concentration. Thus, before evaluating the clinical utility of this combination of drugs, pharmacokinetic studies evaluating the existence of significant pharmacokinetic interactions between both are necessary
Interventions
Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
DRUGNevirapine (Viramune)
Nevirapine (Viramune): tablets 200 mg (1 tablet/12h\*)
Sponsors
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Hospital San Jaime de Calella
Germans Trias i Pujol Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age \>=18 years. * Patients infected by HIV-1 (at least one documented positive Western-Blot). * Stable antiretroviral treatment with atazanavir boosted with ritonavir (300/100 mg QD) for at least 14 days. * Absence of acute infections and/or tumours in the three months prior to inclusion. * Subject able to follow the treatment period. * Transaminase values (AST/ALT) below 5 times the upper limit of the interval of normality. * In women, negative pregnancy test or not of fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or undertaking to use a barrier contraceptive method during the study. * Signature of the informed consent. * Undetectable viral load.
Exclusion criteria
* Failure to comply with any of the inclusion criteria. * Record of allergic hypersensitivity or intolerance to the investigational medication. * Any clinical or historic observation that might interfere in the pharmacokinetics of the medication, such as gastrointestinal diseases or surgery (except herniotomy or appendectomy), alterations in the composition of plasma proteins, any indication of hepatic or renal dysfunction. * Patients that have been given tenofovir, omeprazole or other proton pump inhibitors or any other medication with relevant interactions with atazanavir within the two weeks prior to the screening visit. * Active consumption of alcohol (\> 50 g/day) or illegal drugs (except cannabis). * Suspicion of unsuitable antiretroviral treatment compliance. * Pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the study will be the atazanavir plasma concentration | at baseline and week 4 |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with atazanavir plasma concentrations < 0.15 mg/L | at baseline and week 4 |
| Proportion of patients with nevirapine plasma concentrations > 6.0 mg/L | at baseline and week 4 |
| Incidence of adverse events and anomalies in the laboratory tests (haemogram, AST / ALT / FA / GGT, bilirubin, creatinine, urea). | during the 8 weeks of follow-up |
Countries
Spain
Outcome results
None listed